Cardiovascular Safety in Drug Development: State-of-the-art Assessments

Date(s) And Time(s):
Apr 13 2011 8:00AM - Apr 15 2011 5:00PM

L'Enfant Plaza Hotel
480 L'Enfant Plaza Southwest
Washington, DC 20024-0478

Improve Your Safety Analysis During Drug Development and Analyze and Mitigate Potential Risks.
Participate in debate-style presentations and hear commentary and presentations from international industry, academic, and regulatory speakers to help you optimize your cardiovascular safety assessment.

• QT issues in drug development
• Ischemic events
• Bleeding, blood pressure
• Cardiomyopathy
• Left ventricular dysfunction
• In what situations outcomes studies are necessary
• Benefit-to-risk ratio

April 13, 2011, 1:30-5:00 pm
An Introduction to Clinical Assessment of QT Prolongation in Drug Development
Preregistration is required.

Target Audience:
• Academic scientists
• Industry management
• Clinical project physicians
• Quality assurance directors
• Preclinical/discovery scientists
• ECG safety data managers
• ECG lab and equipment vendors
• Regulatory specialists
• Clinical project management
• Safety assessment personnel

Event Code:

Contact Information:
Rachel Minnick
Program Developer
Phone +1.215.442.6131 begin_of_the_skype_highlighting +1.215.442.6131 end_of_the_skype_highlighting
Fax +1.215.442.6199

Fax +1.215.442.6199